This has been confirmed particularly in patients with lung cancer, in which high expression levels of CDKN1A with wild-type EGFR status was associated with better survival, whereas CDKN1A expression with oncogenic EGFR mutations was correlated with poor outcome [47]. This evidence concerns the gene CDKN1A and lung cancer.